SynthesisClinical rheumatology2012
Intravenous immunoglobulin therapy in adult patients with polymyositis/dermatomyositis: a systematic literature review.
Synthesis in Clinical rheumatology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- Non-targeted immunosuppressive and immunomodulatory therapies for idiopathic inflammatory myopathies.The Cochrane database of systematic reviews · 2025Pooled it
- Targeted immunosuppressive and immunomodulatory therapies for idiopathic inflammatory myopathies.The Cochrane database of systematic reviews · 2025Pooled it
- Rapid improvement of systemic sclerosis-associated intestinal pseudo-obstruction with intravenous immunoglobulin administration.Rheumatology (Oxford, England) · 2023Pooled it
- Theoretical-Experimental Analysis to Elucidate the Mechanism of Action of Novel Anabolic Agents.Molecules (Basel, Switzerland) · 2025Article
- Dermatomyositis following resection of thyroid and breast cancer: a case report and literature review.Frontiers in oncology · 2025Article
- Chronic intestinal pseudo-obstruction in the course of systemic sclerosis successfully treated with intravenous immunoglobulins and rituximab.Reumatologia · 2025Article
- Role of intravenous immunoglobulins in the management of systemic lupus erythematosus: a single-centre experience.Lupus science & medicine · 2024Article
- A Challenging Inflammatory Myopathy Case-Report: Dermatomyositis-Like Rash in an Anti-HMGCR Positive Patient with an Uncertain Muscle Histology.Mediterranean journal of rheumatology · 2023Article
- Mogamulizumab-Associated Myositis With and Without Myasthenia Gravis and/or Myocarditis in Patients With T-Cell Lymphoma.The oncologist · 2023Article
- Disease burden and treatment sequence of polymyositis and dermatomyositis patients in Japan: a real-world evidence study.Clinical rheumatology · 2022Observational
- Expanding the Role of the Pharmacist: Immunoglobulin Therapy and Disease Management in Neuromuscular Disorders.Journal of pharmacy practice · 2022Review
- Dysphagia during glucocorticoid treatment of dermatomyositis: a differential diagnostic challenge.Rheumatology advances in practice · 2018Article
- Recovery from severe dysphagia in systemic sclerosis - myositis overlap: a case report.African health sciences · 2017Article
- Review
- Investigation into the cause of mortality in 49 cases of idiopathic inflammatory myopathy: A single center study.Experimental and therapeutic medicine · 2016Article
- Efficacy of Intravenous Immunoglobulin in Neurological Diseases.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2016Review
- Cost-utility analysis of intravenous immunoglobulin for the treatment of steroid-refractory dermatomyositis in Thailand.PharmacoEconomics · 2015Article
- Biologics in dermatology: an integrated review.Indian journal of dermatology · 2014Review
- Latest advances in connective tissue disorders.Therapeutic advances in musculoskeletal disease · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objectives of this study are to review and summarize published information on the use, effectiveness, and adverse effects of intravenous immunoglobulin (IVIG) in patients with polymyositis (PM) or dermatomyositis (DM) and to search MEDLINE and CNKI (Chinese) databases from 1985 to 2011 to retrieve clinical research articles concerning IVIG in adult patients with PM/DM. Of the 14 articles selected, two were randomized controlled trials, nine prospective open studies, and three retrospective studies with a total of 308 adult patients. IVIG has been used successfully in the treatment of PM/DM. The standard dose is 2 g/kg, given in two to five individual daily doses. The course of IVIG treatment is usually 3~6 months. IVIG therapy seemed rarely employed as first-line therapy in PM/DM. In a double-blind study conducted in patients with refractory DM, IVIG combined with corticosteroid significantly improved muscle strength and decreased serum creatine kinase level, compared with placebo. The beneficial effect of IVIG in refractory, flare-up, rapidly progressive, or severe PM/DM has been documented in many open-label trials. IVIG was shown to be effective in most of PM/DM patients with lung involvement and esophageal involvement. In some patients, IVIG can lower the corticosteroid dose required for maintenance, demonstrating the most effective steroid-sparing effect. Adverse effects were generally tolerable. IVIG is effective in the treatment of adult patients with PM/DM and appears to be relatively well tolerated and safe. IVIG may be a good choice especially in patients with refractory, flare-up, rapidly progressive, or severe PM/DM, and can be tried in patients with a contraindication for corticosteroid.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.